Enpp-1-IN-14 is a potent and selective inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), making it a valuable tool in cancer immunotherapy research. By inhibiting ENPP1, this compound enhances the cGAS-STING signaling pathway, which plays a critical role in innate immune activation. This leads to increased production of type I interferons and improved dendritic cell activation, promoting stronger T-cell responses against tumors. It is particularly studied in models of resistant or immunologically "cold" tumors, where boosting STING activity can help convert the tumor microenvironment into a more immune-responsive state. Enpp-1-IN-14 has shown efficacy in enhancing the effects of immune checkpoint inhibitors, such as anti-PD-1 therapy, suggesting its potential as a combination treatment in oncology. Additionally, due to ENPP1’s role in hydrolyzing extracellular ATP and generating immunosuppressive adenosine, inhibition with Enpp-1-IN-14 helps reduce adenosine-mediated suppression of immune cells in the tumor milieu. This dual action—boosting immune activation while dampening immunosuppression—positions Enpp-1-IN-14 as a promising candidate for development in immuno-oncology therapeutics.